Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
KYNTRA BIO, INC. shareholders approved Advisory vote on executive compensation at the 2026-06-12 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2026-06-12
Exact text from the filing
The stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the 2026 definitive proxy statement filed on April 27, 2026: 1,242,005 shares of Common Stock voted for, 23,606 against, 24,639 abstaining, and 1,444,428 broker non-votes.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
KYNTRA BIO, INC. shareholders approved Ratification of PricewaterhouseCoopers LLP as independent registered public accounting firm at the 2026-06-12 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2026-06-12
Exact text from the filing
The stockholders ratified the selection of PricewaterhouseCoopers LLP, by the Audit Committee of the Kyntra Bio board of directors, as the independent registered public accounting firm of the Company for the year ending December 31, 2026: 2,712,825 shares of Common Stock voted for, 14,392 against, and 7,461 abstaining.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
KYNTRA BIO, INC. shareholders approved Election of Class III director nominee Michael Kauffman, M.D., Ph.D. at the 2026-06-12 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2026-06-12
Exact text from the filing
The Class III director nominee, Michael Kauffman, M.D., Ph.D., was elected to hold office until the Company’s 2029 annual meeting of stockholders. The director received 96.04% of the shares voting: 1,239,169 shares of Common Stock voted for, 0 against, 51,081 withheld, and 1,444,428 broker non-votes.
View on SEC.gov